ACM
NTLA icon

ADAR1 Capital Management’s Intellia Therapeutics NTLA Stock Holding History

ADAR1 Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,517
Closed -$250K – 324
2026
Q1 		$250K Buy
+19,517
New +$249K 0.01% 249
2024
Q4 		– Sell
-800
Closed -$16.4K – 276
2024
Q3 		$16.4K Buy
+800
New +$18.4K ﹤0.01% 245

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

ADAR1 Capital Management's NTLA Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 19,517 shares — an estimated $250K sold.

ADAR1 Capital Management first reported a position in NTLA in Q3 2024 and held it in 2 quarters. The position peaked at $250K in Q1 2026. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • ADAR1 Capital Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 19,517 Intellia Therapeutics shares in Q2 2026, an estimated $250K.
  • ADAR1 Capital Management first reported a position in Intellia Therapeutics in Q3 2024 and held it in 2 quarters.
  • ADAR1 Capital Management's Intellia Therapeutics position peaked at $250K in Q1 2026.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.